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Eruptive melanocytic nevi (EMN) are an unusual
phenomenon characterized by the rapid appearance
of multiple melanocytic nevi. Whether atypical or
benign, EMN are associated with various medications
and diseases but not previously with melanoma.1
EMN have been described in internal malignancy,
such as prostate cancer, in which it is proposed as a
paraneoplastic phenomenon, although the mecha-
nism is unclear.2
One cutaneous phenomenon that arises from
primary melanoma is epidermotropic metastatic
malignant melanoma (EMMM), whereby malignant
cells migrate from the dermal metastasis into the
epidermis. Epidermotropic metastases are metachro-
nous with the primary tumor or appear after re-
section or treatment of the primary disease, and
melanoma is no exception.3 Eruptive nevi may be
clinically mistaken as EMMM; therefore, making the
distinction is important.
We report a case of a patient who had 2 concur-
rent primary melanomas treated with wide local
resection and in whom EMN developed, with no
signs of EMMM, 8 weeks before diagnosis of wide-
spread metastatic melanoma.CASE REPORT
An 80-year-old man presented with a 3.2-cm 3
2.6-cm pink-brown thin plaque with irregular bor-
ders and color variation on the vertex of the scalp.
The lesion was present for 1 year. After referral to a
dermatologist, a total body skin examination also
revealed a 1.3-cm 3 1.0-cm dark brown patch of
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notable for significant cardiovascular disease, an
arrhythmia, chronic renal insufficiency, and Barrett’s
esophagus, which was under periodic surveillance.
Recently, he was hospitalized for methicillin-resistant
staphylococcus aureus bacteremia and received a
long course of intravenous antibiotics. Of note,
results of his last screening colonoscopy were unre-
markable, and he had no family history of melanoma.
Biopsy of the scalp lesion showed at least a 0.85-
mm-thick melanoma, extending to the base (Clark’s
level III). Biopsy of the ala lesion showed a 1.6-mm-
thick melanoma (Clark’s level IV) (Fig 1). The patient
underwent local resection of both tumors, but
because of his medical comorbidities, a sentinel
lymph node biopsy was not performed. Histology
from the removed tissue on the scalp found a 2-mm-
thick melanoma (Clark’s level IV) with intravascular
invasion and negative margins, with staging deter-
mined to be pT3a. The nasal ala tissue showed a 1.8-
mm-thick melanoma (Clark’s level IV) consistent
with stage pT2a, however, with residual melanoma
in situ at the surgical margins. After 3 months of
treatment with topical imiquimod 5% cream and
tazarotene 0.1% gel on the melanoma in situ lesion, 2
scouting biopsies of that area showed reactive
changes and dermal fibrosis with no residual atypical
melanocytes.JAAD Case Reports 2015;1:74-6.
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Fig 2. Eruptive nevi. At a follow-up visit 11 months after
the initial diagnosis of melanoma, numerous monomor-
phic, 1- to 2-mm dark brown to black macules were noted
scattered on the patient’s back and posterior shoulders
consistent with eruptive melanocytic nevi. On dermo-
scopic examination, these macules showed darker irreg-
ular centers. Because their appearance was concerning,
histologic examination was indicated.
Fig 3. Histologic examination of an eruptive nevus. There
is a compound melanocytic nevus composed of mostly
single, small, and monomorphous melanocytes in the
epidermis and in the papillary dermis. The melanocytes
exhibit heavily pigmented cytoplasm. Numerous mela-
nophages are seen in the papillary dermis at the base of
the lesion.
Fig 4. Development of ITM. More than 1 year after the
initial diagnosis, the patient presented with five 5-mm firm
nodules arranged in a linear pattern on the left parietal, left
postauricular, and left mastoid scalp. Histologic examina-
tion found in-transit melanoma metastases.
Fig 1. Histopathologic examination of the melanoma on
the nose. There is irregular proliferation of melanocytes in
the epidermis and in the dermis. The melanocytes are
arranged in nests, which vary in size and shape. Single
melanocytes are seen at the dermal epidermal junction
and down a hair follicle. The melanocytes are pleomor-
phic. Some melanocytes display hyperchromatic nuclei,
prominent nucleoli, and melanin pigment in their cyto-
plasm. A mitotic figure (arrow) is shown.
JAAD CASE REPORTS
VOLUME 1, NUMBER 2
Kibbi et al 75Eleven months after the initial diagnosis, a routine
surveillance total body skin examination showed
dozens of new, 1- to 2-mm monomorphic, dark
brown to black macules scattered on the patient’s
back and posterior shoulders (Fig 2), some with
darker, irregularly pigmented centers on dermo-
scopy. The lesions were consistent with new erup-
tive nevi, and histologic examination of a lesion on
the left shoulder found a compound melanocytic
nevus without histologic atypia (Fig 3). Importantly,
genetic testing of 2 eruptive nevi and the resected
scalp melanoma were BRAF and NRAS wild type.Eight weeks later, the number of nevi had
increased and now involved the patient’s chest. He
also had five 5-mm firm nodules, arranged in a linear
pattern along the left scalp, concerning for in-transit
metastases (ITM; Fig 4). Excision of one scalp nodule
confirmed the diagnosis of ITM, consistent with T3b,
N3, M0, or stage IIIC.
One week later, the patient had increased abdom-
inal girth. Laboratory tests found worsening kidney
and liver functions, and magnetic resonance imaging
found multiple hepatic and peritoneal metastases.
The patient refused further workup and died within
1 week, likely from hepatorenal syndrome.
DISCUSSION
This case highlights the curious development of
EMN heralding the diagnosis of metastatic melanoma
in a patient with a recent history of 2 deep primary
JAAD CASE REPORTS
MARCH 2015
76 Kibbi et almelanomas. The possibility of EMMM was consid-
ered as an explanation for the sudden appearance of
the numerous pigmented macules. In our case, the
histology of the eruptive nevi did not exhibit changes
characteristic of EMMM, such as epidermal thinning
or atypical melanocytes within the dermis and intra-
dermal endothelial-lined spaces.4
Although the phenomenon of EMN remains un-
clear, at least 3 etiologies have been proposed. Some
investigators argue that an immunocompromised
state favors melanocytic proliferation.5 This argu-
ment has been supported by multiple observations,
including the emergence of dysplastic EMN in 7 AIDS
patients concurrently with the increase in viral load
and disease burden.6 In our patient, chronic renal
insufficiency and a recent long course of low-dose
steroids may have contributed to a state of immuno-
compromise culminating in methicillin-resistant
staphylococcus aureus bacteremia.
Survival and progrowth factors are also impli-
cated in the etiology of EMN. For example, fibro-
blast growth factor, which is found to play a role in
the pathogenesis of prostate cancer and bullous
dermatoses, is also a key regulator of melanocytic
proliferation.2,7 Moreover, a synthetic analogue of
a-melanocyteestimulating hormone, an inducer of
melanogenesis, is associated with darkening of
dysplastic nevi and the emergence of EMN.8 As
such, melanocytic mitogens not only affect EMN but
may predispose neoplastic lesions to acquire more
aggressive features, which in our patient may have
simultaneously spurred metastasis and EMN.
EMN may also result from the displacement of
normal melanocytes by malignant melanoma cells
into the lymphatic system.9 This theory, known as
the mechanical transport model, is supported by the
fact that normal nevic melanocytes have been found
in the lymph nodes of melanoma patients. Curiously,our patient did have obvious ITM shortly after the
eruptive nevi were observed, suggesting that locore-
gional lymphatic spread may have been responsible
for dissemination of both malignant and benign
melanocytes.
Here we report a case of an 80-year-old whiteman
with a history of 2 concurrent primary melanomas in
whom EMN developed 11 months after his mela-
noma diagnoses and 8 weeks before presentation
with ITM, followed shortly by terminal metastatic
disease. This is a unique report of EMN presenting
in the setting of in-transit and visceral metastatic
melanoma.
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